Robert Elliot Zipkin

This inventor holds 13 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Biochemical Assays. Top assignees: Enzo Therapeutics, Inc., Virginia Commonwealth University, Enzo Life Sciences, Inc.. Active years: 2009-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert Elliot Zipkin. Retrieved from https://idiyas.com/inventor/robert-elliot-zipkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 13 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 179(Granted Patents)

Company Filing History:

9 out of 31

Enzo Therapeutics, Inc.

patents

5 out of 420

Virginia Commonwealth University

patents

3 out of 99

Enzo Life Sciences, Inc.

patents

4. 1 out of 1

Biomol International LP

where one patent can have more than one assignee

Years Active: 2009-2024

Loading Chart...

Areas of Expertise:

Hydroxycholesterol

Immunoassay

Sphingosine Kinase

Inhibitors

Lifespan Manipulation

Stress Response

Biochemical Compositions

Cellular Processes

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11971419 - Hydroxycholesterol immunoassay (2024-04-30),

2. 11737992 - Sphingosine kinase Type 1 inhibitors and uses thereof (2023-08-29),

3. 10945971 - Sphingosine kinase type 1 inhibitors and uses thereof (2021-03-16),

4. 10624863 - Sphingosine kinase type 1 inhibitors and uses thereof (2020-04-21),

5. 10456370 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-10-29),

6. 10197583 - Hydroxycholesterol immunoassay (2019-02-05),

7. 10166204 - Sphingosine kinase type 1 inhibitors and uses thereof (2019-01-01),

8. 9974758 - Sphingosine kinase type 1 inhibitors and uses thereof (2018-05-22),

9. 9388121 - Sphingosine kinase type 1 inhibitors (2016-07-12),

10. 8969525 - Hydroxycholesterol immunoassay (2015-03-03),

11. 8372888 - Sphingosine kinase type 1 inhibitors, compositions and processes for using same (2013-02-12),

12. 8314151 - Sphingosine kinase type 1 inhibitors, and processes for using same (2012-11-20),

13. 7544497 - Compositions for manipulating the lifespan and stress response of cells and organisms (2009-06-09),

Title: The Innovative Contributions of Robert Elliot Zipkin

Introduction

Robert Elliot Zipkin is a notable inventor based in Wynnewood, Pennsylvania. He has made significant contributions to the field of biomedical research, holding a total of 13 patents. His work primarily focuses on immunoassays and pain management therapies.

Latest Patents

One of his latest patents is the Hydroxycholesterol immunoassay. This invention provides an antibody composition that specifically binds to various hydroxycholesterols, including 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol, and 27-hydroxycholesterol. Additionally, it includes methods for making these antibodies and a kit for detecting these specific hydroxycholesterols. Another significant patent is related to Sphingosine kinase Type 1 inhibitors, which are useful in treating neuropathic pain.

Career Highlights

Throughout his career, Robert has worked with prominent organizations such as Enzo Therapeutics, Inc. and Virginia Commonwealth University. His innovative research has contributed to advancements in medical diagnostics and therapeutic treatments.

Collaborations

Robert has collaborated with notable individuals in his field, including Jeffrey Kroll Adams and Sarah Spiegel. Their combined expertise has furthered the development of his patented technologies.

Conclusion

Robert Elliot Zipkin's contributions to biomedical research through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to impact medical science and improve patient care.

Profile summary based on public USPTO records.